TranScrip Partners is pleased to announce that the company has become a member of The Association of the British Pharmaceutical Industry (ABPI), a move which reflects TranScrip’s status as a rapidly growing, cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. The ABPI, which represents innovative research-based biopharmaceutical companies, large, medium and small, is leading an exciting new era of biosciences in the UK.
“We are a unique CRO operating as a Limited Liability Partnership with two extensively experienced Senior Partners and a powerful global supporting team of staff who have completed more than £10m worth of clinical and regulatory projects mostly for big pharma research-based biopharmaceutical companies” says Founding and Managing Partner, Dr Flic Gabbay. “TranScrip is based in the UK and like the new ABPI we wish to help the UK lead biopharmaceutical research. Therefore our ethos is well aligned with the ABPI vision. We hope quickly to become integrated in the various ABPI-led networks of expert groups, companies and research and development networks, since we have the expertise and the capability to help ABPI’s effort towards an exciting new era of biosciences in the UK.”
This milestone in TranScrip’s evolution comes at the time of the fourth anniversary of its foundation. Since then, the partnership has grown to become an organisation of 20 Senior Partners, 5 Partners and support staff. TranScrip has offices in the UK, Australia, and soon in the USA. The range of expertise has grown to encompass infectious diseases, oncology, CNS/pain, internal medicine and respiratory therapy areas. TranScrip looks forward to future expansion and to leading the evolution of the role of the contract organisation in the biopharmaceutical industry.